What is HC Wainwright’s Estimate for RMTI FY2025 Earnings?

Rockwell Medical, Inc. (NASDAQ:RMTI) – Analysts at HC Wainwright upped their FY2025 earnings estimates for Rockwell Medical in a report issued on Monday, January 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.09) for the year, up from their prior estimate of ($0.17). HC Wainwright has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2025 earnings at $0.04 EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.03) EPS.

Several other brokerages have also issued reports on RMTI. Wall Street Zen lowered Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $2.50.

Rockwell Medical Price Performance

Rockwell Medical stock opened at $1.13 on Wednesday. The business’s 50 day simple moving average is $0.94 and its 200 day simple moving average is $1.11. Rockwell Medical has a 12 month low of $0.78 and a 12 month high of $2.12. The company has a market cap of $44.52 million, a price-to-earnings ratio of -7.06 and a beta of 1.65. The company has a current ratio of 3.91, a quick ratio of 3.50 and a debt-to-equity ratio of 0.25.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RMTI. Panagora Asset Management Inc. bought a new stake in shares of Rockwell Medical during the second quarter valued at about $41,000. GSA Capital Partners LLP grew its stake in Rockwell Medical by 635.1% during the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after acquiring an additional 141,672 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Rockwell Medical by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares during the period. Institutional investors own 23.31% of the company’s stock.

Key Headlines Impacting Rockwell Medical

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Zacks upgraded RMTI to a Zacks Rank #2 (Buy), signaling improving earnings prospects that could attract buyers. Rockwell Medical (RMTI) Upgraded to Buy: Here’s What You Should Know
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, raised multiple quarterly and full‑year EPS estimates and maintains a $2.50 price target — analyst upgrades and tighter forecasts can support a higher share price if guidance/earnings follow. HC Wainwright Reaffirms “Buy” Rating for Rockwell Medical (NASDAQ:RMTI)
• Positive Sentiment: Zacks published pieces highlighting RMTI as undervalued and as a “fast‑paced momentum at a bargain” name — increased retail/institutional interest from such screens can boost demand. Is Rockwell Medical (RMTI) Stock Undervalued Right Now? Despite Fast-paced Momentum, Rockwell Medical (RMTI) Is Still a Bargain Stock
• Positive Sentiment: Short interest fell about 32% in January (to ~580.6k shares), reducing potential short‑term selling pressure and lowering a short‑squeeze risk profile — generally supportive for the share price.
• Neutral Sentiment: Company fundamentals/technicals: small market cap (~$45M), negative trailing P/E, elevated beta (1.65). The stock sits between its 50‑day (~$0.94) and 200‑day (~$1.11) moving averages, indicating mixed momentum with limited liquidity—this can amplify moves both ways.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.